Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
May 31, 2026 -2.660M
February 28, 2026 -2.534M
November 30, 2025 -2.573M
August 31, 2025 -2.496M
May 31, 2025 -2.537M
February 28, 2025 -2.570M
November 30, 2024 -2.514M
August 31, 2024 -2.48M
May 31, 2024 -2.454M
February 29, 2024 -2.358M
November 30, 2023 -2.095M
August 31, 2023 -2.017M
May 31, 2023 -1.909M
February 28, 2023 -2.012M
November 30, 2022 -1.974M
August 31, 2022 -1.632M
May 31, 2022 -1.182M
February 28, 2022 -0.648M
November 30, 2021 0.6274M
August 31, 2021 1.806M
May 31, 2021 2.332M
February 28, 2021 3.783M
November 30, 2020 1.256M
August 31, 2020 1.764M
May 31, 2020 5.098M
Date Value
February 29, 2020 3.152M
November 30, 2019 6.021M
August 31, 2019 14.74M
May 31, 2019 19.32M
February 28, 2019 17.97M
November 30, 2018 9.071M
August 31, 2018 2.646M
May 31, 2018 2.636M
February 28, 2018 3.248M
November 30, 2017 2.422M
August 31, 2017 2.939M
May 31, 2017 2.877M
February 28, 2017 -0.2779M
November 30, 2016 -0.1055M
August 31, 2016 -0.4674M
May 31, 2016 -0.3989M
February 29, 2016 -0.3982M
November 30, 2015 0.1573M
August 31, 2015 -0.3096M
May 31, 2015 -0.1733M
February 28, 2015 -0.0471M
November 30, 2014 0.0101M
August 31, 2014
May 31, 2014 -0.0038M
February 28, 2014 -0.0499M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 1.044M
GB Sciences, Inc. --
Arvinas, Inc. 562.20M
Fulcrum Therapeutics, Inc. 310.70M
Definium Therapeutics, Inc. 918.68M

Shareholders Equity (Quarterly) Related Metrics